Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–34 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Optive Clear all
Completed Not applicable Interventional Results available

Evaluation of SYSTANE Ultra Lubricant Eye Drops

NCT00702377
View directory record Official record
Conditions
Dry Eye
Interventions
SYSTANE Ultra, Optive
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms

NCT00405457
View directory record Official record
Conditions
Dry Eye
Interventions
Restasis, Optive Tears
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear

NCT00691197
View directory record Official record
Conditions
Ametropia
Interventions
Carboxymethylcellulose sodium and Glycerin, Carboxymethylcellulose sodium
Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Not applicable Interventional Results available

Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops

NCT00756093
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops, Blink Tears, GenTeal Moderate Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 20, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 20, 2026, 6:16 AM EDT